Pharmacokinetic Study of Paclitaxel Concentration after Drug-Eluting Balloon Angioplasty in the Iliac Artery of Healthy and Atherosclerotic Rabbit Models

Journal of Vascular and Interventional Radiology

Volumn 26, Issue 9, 2015, Pages 1380-1387.e1

  Fernández Parra, Rocío ^a,b   Laborda, Alicia ^a,b   Lahuerta, Celia ^b   Lostalé, Fernando ^a   Aramayona, Jose ^a   De Blas, Ignacio ^a   De Gregorio, Miguel A ^a,b,c  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b Group Interventional Technics Minimal Invasive (GITMI)   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACLITAXEL; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELUTING BALLOON ANGIOPLASTY; HISTOPATHOLOGY; ILIAC ARTERY; LIQUID CHROMATOGRAPHY; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANIMAL; DRUG ELUTING STENT; METABOLIC CLEARANCE RATE; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES; RABBIT; SURGERY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; ANIMALS; ATHEROSCLEROSIS; COMBINED MODALITY THERAPY; DRUG-ELUTING STENTS; ILIAC ARTERY; MALE; METABOLIC CLEARANCE RATE; PACLITAXEL; RABBITS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84940449344     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2015.05.022     Document Type: Article

References (27)

1. M. Balcells, J. Martorell, C. Olive, and et al. Smooth muscle cells orchestrate the endothelial cell response to flow and injury Circulation 121 2010 May 25 2192 2199 10.1161/CIRCULATIONAHA.109.877282
2. N.M. Pires, D. Eefting, M.R. de Vries, P.H. Quax, and J.W. Jukema Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries Heart 93 2007 Aug 922 927
3. B. Scheller Opportunities and limitations of drug-coated balloons in interventional therapies Herz 36 2011 May 232 239 10.1007/s00059-011-3462-3
4. A.R. Tzafriri, A.D. Levin, and E.R. Edelman Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery Cell Prolif 42 2009 Jun 348 363 10.1111/j.1365-2184.2009.00602.x
5. T.J. Parry, R. Brosius, R. Thyagarajan, and et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries Eur J Pharmacol 524 2005 Nov 7 19 29 Epub 2005 Nov 3. PubMed PMID: 16271360
6. E. Stabile, V. Virga, L. Salemme, and et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis J Am Coll Cardiol 60 2012 Oct 30 1739 1742 10.1016/j.jacc.2012.07.033
7. J. Wiskirchen, W. Schober, N. Schart, and et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study Invest Radiol 39 2004 Sep 565 571
8. A. Lupi, A. Rognoni, G.G. Secco, and et al. Drug eluting balloon versus drug eluting stent in percutaneous coronary interventions: insights from a meta-analysis of 1462 patients Int J Cardiol 168 2013 Oct 12 4608 4616 10.1016/j.ijcard.2013.07.161
9. K. Katsanos, S. Spiliopoulos, N. Karunanithy, M. Krokidis, T. Sabharwal, and P. Taylor Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery J Vasc Surg 59 2014 Apr 1123 1133 10.1016/j.jvs.2014.01.041 e8
10. G. Tepe, J. Laird, P. Schneider, and et al. IN.PACT SFA Trial Investigators∗. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial Circulation 131 2015 Feb 3 495 502 10.1161/CIRCULATIONAHA.114.011004 Epub 2014 Dec 3
11. D. Scheinert, S. Duda, T. Zeller, and et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty JACC Cardiovasc Interv 7 2014 Jan 10 19 10.1016/j.jcin.2013.05.022
12. A.R. Tzafriri, N. Vukmirovic, V.B. Kolachalama, I. Astafieva, and E.R. Edelman Lesion complexity determines arterial drug distribution after local drug delivery J Control Release 142 2010 Mar 19 332 338 10.1016/j.jconrel.2009.11.007
13. G. Tepe, S. Schmitmeier, and T. Zeller Drug-coated balloons in peripheral arterial disease EuroIntervention 7 2011 May K70 K76 10.4244/EIJV7SKA13
14. C.J. Creel, M.A. Lovich, and E.R. Edelman Arterial paclitaxel distribution and deposition Circ Res 86 2000 Apr 28 879 884
15. A.D. Levin, N. Vukmirovic, C.W. Hwang, and E.R. Edelman Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel Proc Natl Acad Sci U S A 101 2004 Jun 22 9463 9467
16. D.P. Faxon, T.A. Sanborn, V.J. Weber, and et al. Restenosis following transluminal angioplasty in experimental atherosclerosis Arteriosclerosis 4 1984 May-Jun 189 195
17. M.D. Ferrer, E. Esteban, F. Liste, and et al. The rabbit as an experimental model: technique for the induction of vascular lesions and incidents Radiologia (Panama) 52 2010 Jan-Feb 45 50 10.1016/j.rx.2009.09.011
18. S.C. Kim, J. Yu, J.W. Lee, E.S. Park, and S.C. Chi Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution J Pharm Biomed Anal 39 2005 Sep 1 170 176
19. C. Herdeg, M. Oberhoff, A. Baumbach, and et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo J Am Coll Cardiol 35 2000 Jun 1969 1976
20. D.I. Axel, W. Kunert, C. Goggelmann, and et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery Circulation 96 1997 Jul 15 636 645
21. W.C. Dornas, T.T. Oliveira, L.E. Augusto, and T.J. Nagem Experimental atherosclerosis in rabbits Arq Bras Cardiol 95 2010 Aug 272 278
22. F.D. Kolodgie, A.S. Katocs Jr, E.E. Largis, and et al. Hypercholesterolemia in the rabbit induced by feeding graded amounts of low level cholesterol. Methodological considerations regarding individual variability in response to dietary cholesterol and development of lesion type Arterioscler Thromb Vasc Biol 16 1996 Dec 1454 1464
23. H.C. Stary, A.B. Chandler, R.E. Dinsmore, and et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association Circulation 92 1995 Sep 1 1355 1374
24. M. Aikawa, E. Rabkin, Y. Okada, and et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization Circulation 97 1998 Jun 23 2433 2444
25. A. Posa, N. Nyolczas, R. Hemetsberger, and et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries Catheter Cardiovasc Interv 76 2010 Sep 1 395 403 10.1002/ccd.22468
26. J.F. Granada, M. Stenoien, P.P. Buszman, and et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing Open Heart 1 2014 Aug 6 e000117 10.1136/openhrt-2014-000117
27. B. Radeleff, R. Lopez-Benitez, U. Stampfl, and et al. Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model J Vasc Interv Radiol 21 2010 Aug 1262 1270 10.1016/j.jvir.2010.02.020